D.A. Davidson & CO. Makes New $417,000 Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

D.A. Davidson & CO. purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,244 shares of the company’s stock, valued at approximately $417,000.

A number of other large investors also recently made changes to their positions in the business. Raymond James & Associates raised its position in shares of Amphastar Pharmaceuticals by 1.7% in the 3rd quarter. Raymond James & Associates now owns 116,677 shares of the company’s stock worth $5,662,000 after buying an additional 1,958 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth $11,070,000. Dakota Wealth Management purchased a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth $202,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after buying an additional 301 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Amphastar Pharmaceuticals by 63.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,362 shares of the company’s stock worth $454,000 after buying an additional 3,617 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

AMPH has been the subject of several recent research reports. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Piper Sandler downgraded Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. Finally, Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $50.33.

Insider Activity

In related news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the transaction, the executive vice president now owns 118,469 shares of the company’s stock, valued at $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 0.9 %

Shares of Amphastar Pharmaceuticals stock opened at $31.99 on Wednesday. The business has a 50-day moving average of $35.27 and a 200-day moving average of $42.83. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The company has a market capitalization of $1.54 billion, a PE ratio of 10.66, a P/E/G ratio of 2.19 and a beta of 0.81. Amphastar Pharmaceuticals, Inc. has a 1-year low of $30.34 and a 1-year high of $56.38.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.